The share price has come up by 24% over the past three months.
Redeye is positive on the new CPT III codes for Paxman’s CIPN device.
Redeye retains its positive view of Formpipe following a mixed Q4 report, which showed strong profit...
Redeye makes some downward adjustments to our near-term forecasts as order bookings have been slow l...
* Q4 Paper EBIT of ~PLN 13.2m * Lower wood costs ahead, but markets still challenging * Fair value r...
* Adj. EBITA margin up 1.7pp as sales grew 15% ex. M&A * Likely to exceed conservative guidance in '...
* FY guidance as expected, but Q1 comments ahead of plan * '26e adj.
Redeye updates its estimates following Safeture’s Q4 2025 results, which showed continued sequential...
Adtraction redovisade ökad nettoomsättning och EBITA i det fjärde kvartalet.
Beyond Frames redovisade totala intäkter om 39,8 MSEK (50,9), varav nettoomsättningen uppgick till 2...
Train Alliance ended 2025 with a bang. The last land transaction was carried out at a 61% premium to...
Systemair väntas leverera ett starkt tredje kvartal med fortsatt organisk tillväxt och stigande marg...
En nordisk detaljhandelsjätte står inför ett vägskäl med stor potentiell uppsida om synergier från e...
Omsättningen föll till 7,8 MEUR (-17%) p.g.a. omförhandlade B2B-avtal, men bruttomarginalen steg kra...
Redeye provides a research update following the Q4 report recently published by Initiator Pharma.
Redeye comments on Oncopeptides’ Q4 report. Sales declined by 8% versus Q3 2025 when growth was expe...
Tradedoubler reported FY25 revenue growth of 5% (8% in constant currency), with another year of mode...
Fastighetsbolaget Trianons förvaltningsresultat per aktie ökade med 27 procent under 2025 jämfört me...
Case Group levererar på årsbasis fortsatt stark tillväxt och förbättrad lönsamhet i Q4 2025, med rob...
Redeye comments on Fable Media Group's proposal to distribute SEK 0.
